Furniture some very good points reading PABs ASX announcements...

Furniture some very good points reading PABs ASX announcements over and over again to really appreciate the potential of PAT SM6, PAT SC1 and PAT LM1. As all readers will be aware these are antibodies of the IgM subclass.

Other fundamental points to consider when assessing the potential of Patrys is:
1) THey have in effect achieved the "holy grail" in relation to the upscale and commercial manufacture of IgM's - this is a huge achievement and cannot be underestimated (no other company has been able to do this at this scale, although a few have tried and have been unsuccessful).

2)The huge therapeutic implications that the commercial manufacture of IgM has - not only in oncology. To really appreciate the role (and increasing recognition of this in the scientific literature, I would encourage those who are really interested in the potential of Patrys to read this recent review article on the therapeutic potential of IgM's). As part of the innate and one of the first lines of immune defence IgM's have important roles in dealing not only with cancer, but also bacterial infection, inflammation (such as arthritis) and even alziemers disease (to name a few).

The article may be a bit hard going for some - however provides a good overview of the therapeutic potential of IgM's. Mesoblast eat your heart out!!

http://www.jimmunol.org/content/188/3/939